Evaluation of a sex-based difference in the pharmacokinetics of digoxin

Pharmacotherapy

Volumn 26, Issue 1, 2006, Pages 44-50

  Lee, Lois S ^a   Chan, Lingtak Neander ^a,b,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Body mass index; Body weight; Digoxin; P glycoprotein; Pharmacokinetics; Sex based difference

Indexed keywords

DIGOXIN;

ACCURACY; ADULT; AGED; BODY MASS; BODY WEIGHT; DRUG BLOOD LEVEL; EVALUATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; LEAN BODY WEIGHT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; REVIEW; SEX DIFFERENCE;

AGED; ATRIAL FIBRILLATION; BODY MASS INDEX; BODY WEIGHT; CARDIOTONIC AGENTS; DIGOXIN; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS;

EID: 30544447318     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2006.26.1.44     Document Type: Review

References (53)

1. Semple P, Hope DA, Clyburn P, Rodbert A. Relative potency of vecuronium in male and female patients in Britain and Australia. Br J Anaesth 1994;72(2):190-4.
2. Xue FS, Liao X, Liu JH, et al. Dose-response curve and time-course of effect of vecuronium in male and female patients. Br J Anaesth 1998;80(6):720-4.
3. Xue FS, An G, Liao X, Zou Q, Luo LK. The pharmacokinetics of vecuronium in male and female patients. Anesth Analg 1998;86(6):1322-7.
4. Xue FS, Tong SY, Liao X, Liu JH, An G, Luo LK. Dose-response and time course of effect of rocuronium in male and female anesthetized patients. Anesth Analg 1997;85(3):667-71.
5. Gan TJ, Glass PS, Sigl J, et al. Women emerge from general anesthesia with propofol/alfemanil/nitrous oxide faster than men. Anesthesiology 1999;90(5):1283-7.
6. Vuyk J, Oostwouder CJ, Vletter AA, Burm AG, Bovill JG. Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. Br J Anaesth 2001;86(2):183-8.
7. Floridia M, Bucciardini R, Fragola V, et al, for the ISS-IPI Study Group. Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL). HIV Med 2004;5(1):1-10.
8. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001;32(1):124-9.
9. Antinori A, Baldini F, Girardi E, et al. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001;15(12):1579-81.
10. Gangar M, Arias G, O'Brien JG, Kemper CA. Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. Ann Pharmacother 2000;34(7-8):839-42.
11. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002;3(4):279-86.
12. Bonfanti P, Ricci E, Landonio S, et al, for the CISAI Study Group. Italian coordination for the study of HIV infection and allergies: predictors of protease inhibitor-associated adverse events. Biomed Pharmacother 2001;55(6):321-3.
13. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med 2003;11(2):55-9.
14. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations: women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 2003;34(1):58-61.
15. Brown AM. Drugs, hERG and sudden death. Cell Calcium 2004;35(6):543-7.
16. Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf 2002;1(2):121-8.
17. Clancy CE, Kurokawa J, Tateyama M, Wehrens XH, Kass RS. K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annu Rev Pharmacol Toxicol 2003;43:441-61.
18. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270(21):2590-7.
19. Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001;24(8):575-85.
20. Wolbrette D. Gender differences in the proarrhythmic potential of QT-prolonging drugs. Curr Womens Health Rep 2002;2(2):105-9.
21. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52(6):643-58.
22. Carrillo JA, Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996;41(6):605-8.
23. Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 1999;55(3):177-84.
24. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003;38(4):978-88.
25. Zhu B, Liu ZQ, Chen GL, et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 2003;55(3):264-9.
26. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002;72(5):474-89.
27. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002;41:329-42.
28. Anderson GD. Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase. J Gend Specif Med 2002;5(1):25-33.
29. Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: part 1. J Women Health Gend Based Med 2002;11(7):601-15.
30. The Digitalis Investigation Group. The effects of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
31. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-11.
32. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31-41.
33. Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992;8(7):690-5.
34. Kassotis J, Costeas C, Bedi AK, Tolat A, Reiffel J. Effects of aging and gender on QT dispersion in an overtly healthy population. Pacing Clin Electrophysiol 2000;23(7):1121-6.
35. Hastreiter AR, van der Horst RL. Postmortem digoxin tissue concentration and organ content in infancy and childhood. Am J Cardiol 1983;52(3):330-5.
36. Hastreiter AR, van der Horst RL. Tissue concentrations at autopsy in infants and children receiving therapeutic digoxin. J Forensic Sci 1984;29(1):139-46.
37. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99(4):552-7.
38. Yukawa E, Mine H, Higuchi S, Aoyama T. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. J Pharm Pharmacol 1992;44(9):761-5.
39. Abernethy DR, Greenblatt DJ, Smith TW. Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 1981;102(4):740-4.
40. Anonymous. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr 1998;68(4):899-917.
41. Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the heart and estrogen/progestin replacement study: lessons learned. Circulation 2002;105:917-22.
42. Zibera C, Gibelli N, Maestri L, et al. Medroxyprogesterone-acetate reverses the MDR phenotype of the CG5-doxorubicin resistant human breast cancer cell line. Anticancer Res 1995;15:745-50.
43. Orlowski S, Mir LM, Belehradek J Jr, Garrigos M. Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J 1996;317(pt 2):515-22.
44. Wyeth Pharmaceuticals. PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets), PREMPHASE (conjugated estrogens/medroxyprogesterone acetate tablets) product insert. Revised July 15, 2005. Philadelphia, PA; 2004. Available from www.wyeth.com/content/ShowLabeling.asp?id=133. Accessed November 2, 2005.
45. Aebi S, Schnider TW, Los G, et al. A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel. Cancer Chemother Pharmacol 1999;44:259-65.
46. Christen RD, McClay EF, Plaxe SC, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. J Clin Oncol 1993;11:2417-26.
47. Brenner SS, Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol 2004;60:97-102.
48. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002;54(10):1295-310.
49. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003;43:285-307.
50. Tang K, Ngoi SM, Gwee PC, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002;12(6):437-50.
51. Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72(2):209-19.
52. Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001;18(10):1400-4.
53. Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003;58(12):809-12.